Coronavirus Update: Vertex, Pfizer And Others Disclose Trial Disruptions, Viatris Merger Delayed
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
You may also be interested in...
The company reaffirmed 2020 sales and earnings financial guidance, highlighting the resiliency of the business amid a global pandemic, but Pfizer did highlight some potential business challenges.
Earnings preview: Pfizer's newly launched rare disease drug Vyndaqel and vaccines could be impacted by COVID-19. Investors will also be eager to hear more about the timeline for closing the Upjohn transaction.
Vir began pursuing immunological approaches to infectious diseases three years before its COVID-19 work. Its hepatitis B, flu and HIV clinical trials are delayed about six months due to coronavirus-related issues.